Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy
Source: View publication →
In patients with EGFR-mutated advanced NSCLC with MET overexpression or amplification who progressed on osimertinib, the combination of osimertinib and the MET inhibitor savolitinib significantly improved both progression-free and overall survival compared to standard platinum-pemetrexed chemotherapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
The SAFFRON trial establishes a new biomarker-driven, chemotherapy-free standard of care for a difficult-to-treat population. By confirming that MET-driven acquired resistance to osimertinib can be effectively overcome by combining a potent MET inhibitor with continued EGFR suppression, it demonstrates a definitive, dual-targeted overall survival advantage over conventional platinum-doublet salvage therapy. This underscores the critical importance of repeat biopsy and molecular profiling upon disease progression in EGFR-mutated NSCLC.
Historical Context
Osimertinib is the standard first-line therapy for advanced EGFR-mutated NSCLC. However, acquired resistance inevitably develops, with MET amplification or overexpression being a predominant on-target escape mechanism occurring in 15-20% of cases. Historically, patients progressing on frontline osimertinib were broadly transitioned to platinum-based doublet chemotherapy, which provides limited durability. While earlier Phase 2 studies such as the SAVANNAH trial provided proof-of-concept for the activity of combining osimertinib and savolitinib, the SAFFRON Phase 3 trial is the pivotal validation of this strategy in a randomized, controlled setting. It marks a crucial milestone in precision oncology by effectively targeting secondary resistance pathways to prolong survival.
Guided Discussion
High-yield insights from every perspective
How does MET amplification serve as a bypass resistance mechanism to EGFR inhibitors like osimertinib in NSCLC, and why is it therapeutically necessary to continue the EGFR inhibitor alongside a MET inhibitor?
Key Response
MET amplification activates downstream signaling pathways, such as PI3K/AKT and MAPK, independently of EGFR, effectively bypassing the pharmacologic blockade. Continuing osimertinib prevents a flare of the original EGFR-driven tumor growth, while the MET inhibitor (savolitinib) selectively targets the newly acquired bypass resistance pathway.
When a patient with EGFR-mutated NSCLC progresses on first-line osimertinib, what are the standard next steps in molecular testing, and how does this study's finding alter therapeutic options compared to prior standard salvage therapy?
Key Response
Progression on osimertinib necessitates a tissue re-biopsy or ctDNA analysis to identify specific resistance mechanisms, such as C797S mutations, SCLC transformation, or MET amplification. This study demonstrates that identifying MET dysregulation now allows for a targeted, chemotherapy-sparing approach (osimertinib plus savolitinib) that provides superior progression-free and overall survival compared to the traditional default of platinum-pemetrexed chemotherapy.
MET dysregulation can be defined by gene amplification via FISH/NGS or protein overexpression via IHC. How does the specific methodology for detecting MET alterations impact the anticipated depth of response to savolitinib, and what overlapping toxicities between these two TKIs require proactive management?
Key Response
High-level MET amplification (e.g., gene copy number of 5 or more) generally predicts more robust and durable responses to MET TKIs than IHC overexpression alone, which can be biologically heterogeneous. Clinically, combining two potent TKIs increases the risk of overlapping adverse events, most notably severe transaminitis, interstitial lung disease (ILD), and QT interval prolongation, demanding rigorous baseline screening and vigilant dose-modification protocols.
Given the profound overall survival benefit of the osimertinib-savolitinib combination over chemotherapy in the resistance setting, is there a clinical rationale to move this combination to the frontline for high-risk EGFR-mutated patients to prevent MET-driven resistance from developing?
Key Response
While highly effective for acquired MET-driven resistance, deploying this combination universally in the frontline would expose all patients to upfront additive toxicity (like hepatotoxicity) and financial burden, while potentially selecting for more complex, untreatable pan-resistant clones later. The data reinforces a precision-sequencing paradigm: maximizing the durability of single-agent osimertinib first, and reserving the combination strictly for those with confirmed MET-driven acquired resistance.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In trials evaluating dual-targeted therapies for acquired resistance, intratumoral heterogeneity and clonal evolution pose major analytical challenges. How should modern trial designs address the competing risk of non-MET dependent subclonal progression when evaluating the true efficacy of this combination?
Key Response
Acquired resistance is rarely monoclonal; patients often harbor simultaneous resistance mechanisms (e.g., MET amplification alongside TP53 or cell cycle mutations). Rigorous trial design must incorporate baseline and longitudinal deep-sequencing ctDNA analysis to accurately distinguish true target failure (MET escape) from off-target subclonal outgrowth, utilizing mixed-effects statistical models or joint modeling of longitudinal mutational burden and clinical survival endpoints.
During peer review, how would you critically appraise the control arm choice of standard platinum-pemetrexed without immunotherapy, and how might post-progression crossover dynamics confound the interpretation of the overall survival endpoint?
Key Response
A rigorous reviewer would question whether platinum-doublet alone remains the absolute modern standard, given debates around incorporating VEGF inhibitors or chemo-immunotherapy regimens (e.g., IMpower150) post-TKI. Additionally, if the control arm lacked access to crossover MET inhibitors upon subsequent progression, the overall survival benefit observed could be artificially inflated by the control group's lack of access to any effective targeted salvage therapy, rather than proving the specific superiority of the immediate combination.
Current NCCN and ASCO guidelines recommend platinum-doublet chemotherapy or clinical trials for EGFR-mutated NSCLC progressing on osimertinib. Based on these phase 3 results showing dual PFS and OS benefits, what specific algorithmic updates and evidence-level assignments are warranted for biomarker testing and treatment?
Key Response
The guidelines must be updated to assign a Category 1 recommendation for the osimertinib plus savolitinib combination as the preferred second-line therapy for patients with confirmed MET-driven resistance post-osimertinib. Crucially, this requires an accompanying mandate in the diagnostic guidelines to ensure that routine progression testing explicitly includes robust assays for MET amplification (via FISH or comprehensive NGS), moving MET testing from a secondary consideration to a mandatory reflex test alongside EGFR C797S evaluation.
Clinical Landscape
Noteworthy Related Trials
AURA3 Trial
Tested
Osimertinib 80mg daily
Population
T790M-positive advanced NSCLC after first-line EGFR-TKI therapy
Comparator
Platinum-pemetrexed chemotherapy
Endpoint
Progression-free survival (PFS)
FLAURA Trial
Tested
Osimertinib 80mg daily
Population
Treatment-naive EGFR-mutated advanced NSCLC
Comparator
Standard EGFR-TKI (gefitinib or erlotinib)
Endpoint
Progression-free survival (PFS)
TATTON Phase 1b/2 Trial
Tested
Osimertinib plus Savolitinib
Population
EGFR-mutated, MET-amplified advanced NSCLC progressing on prior EGFR-TKI
Comparator
None (Single-arm study)
Endpoint
Safety and Objective Response Rate (ORR)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis